Financial Reporting - CĪON Investment Corporation will report its financial results for Q1 2025 on May 8, 2025, before market opening[4] - An earnings conference call to discuss the financial results is scheduled for 11 a.m. Eastern Time on the same day[4] - The press release regarding the financial results is attached as Exhibit 99.1[4]

Financial Performance - Net sales for Q4 fiscal 2025 were $317.9 million, a slight decrease of 0.3% compared to $318.8 million in Q4 fiscal 2024[4] - Net earnings from continuing operations increased 111% to $3.6 million, while adjusted EBITDA from continuing operations grew 35% to $85.1 million[4] - Adjusted EPS from continuing operations (diluted) increased from $0.74 to $1.06 per share[4] - Operating cash flow increased 38% to $62.4 million, and free cash flow rose 46% to $49.3 million[4] - Net earnings for the three months ended May 31, 2025, were $3,614,000, a significant improvement from a net loss of $32,049,000 in the same period of 2024[28] - The company reported a GAAP net earnings of $96,053,000 for the twelve months ended May 31, 2025, compared to $35,243,000 for the same period in 2024[38] - The adjusted EBITDA for the twelve months ended May 31, 2025, was $263,489,000, compared to $250,999,000 for the same period in 2024, indicating a positive trend in operational performance[36] Cash Flow and Dividends - The company ended the quarter with cash of $250.1 million, an increase of $5.9 million from the previous year[10] - Cash and cash equivalents increased to $250,075 thousand as of May 31, 2025, compared to $244,225 thousand in 2024, showing a growth of 2.9%[26] - The company declared cash dividends of $0.17 per share for the three months ended May 31, 2025, compared to $0.16 per share in the same period of 2024[24] - The company paid dividends totaling $33,903,000 for the twelve months ended May 31, 2025, compared to $56,819,000 in the previous year, reflecting a reduction in dividend payments[28] Segment Performance - Building Products segment net sales increased by $38.8 million, or 25.2%, to $192.3 million, driven by higher volumes and contributions from the Ragasco acquisition[13] - The Consumer Products segment reported net sales of $125,568,000 for the three months ended May 31, 2025, slightly up from $125,336,000 in the same period of 2024[31] - The Building Products segment achieved net sales of $192,316,000 for the three months ended May 31, 2025, compared to $153,551,000 in the same period of 2024, marking an increase of 25.2%[31] Impairment and Losses - The impairment of goodwill and long-lived assets for the three months ended May 31, 2025, was $50,813 thousand, up from $32,975 thousand in 2024[24] - The company incurred impairment charges of $50,813,000 for long-lived assets in the three months ended May 31, 2025, compared to $32,975,000 in the same period of 2024[34] Operational Metrics - Total assets rose to $1,695,152 thousand as of May 31, 2025, up from $1,638,637 thousand in 2024, indicating an increase of 3.4%[26] - Total liabilities increased to $756,915 thousand as of May 31, 2025, compared to $747,625 thousand in 2024, reflecting a rise of 1.8%[26] - Net cash provided by operating activities for the twelve months ended May 31, 2025, was $209,744,000, down from $289,976,000 in 2024, representing a decrease of approximately 27.7%[28] - The company’s operating cash flow conversion for the three months ended May 31, 2025, was 1,610%, a significant increase from (143%) in the same period of 2024[38] Acquisitions and Corporate Actions - The acquisition of Elgen Manufacturing was completed for approximately $93 million, enhancing the company's position in the HVAC market[4] - The company repurchased 200,000 shares of common stock for $9.8 million, with 5,365,000 shares remaining on the repurchase authorization[4] Tax and Adjustments - The effective tax rate for the three months ended May 31, 2025, was 54.9%, significantly higher than the effective tax rate of (18.8%) for the same period in 2024[34] - Adjusted operating income is defined as operating income excluding specific items, providing a clearer view of ongoing performance[41] - Adjusted net earnings from continuing operations exclude after-tax effects of certain items, offering a more accurate reflection of profitability[42] - Adjusted EBITDA from continuing operations is used to evaluate segment performance and overall profitability, excluding non-recurring items[43] - Free cash flow is defined as net cash flows from operating activities less investments in property, plant, and equipment, indicating liquidity[44] - Free cash flow conversion measures how much of adjusted net earnings is converted into cash, highlighting cash generation efficiency[45] - Impairment charges and restructuring activities are excluded from non-GAAP measures as they do not reflect ongoing operations[46] - Separation costs related to corporate functions are excluded as they are one-time in nature and not expected to recur[46] - Non-cash charges and losses on extinguishment of debt are excluded to avoid obscuring financial performance analysis[47] - Pension settlement charges and one-time tax effects of separation are excluded due to their non-recurring nature[47] - Corporate costs eliminated at separation reflect overhead costs that no longer exist post-separation, impacting financial reporting[47]

Financial Performance - Greenbrier's net earnings attributable reached $60 million, or $1.86 per diluted share, with revenue of $843 million[5] - The company achieved an aggregate gross margin of 18%[5] - Greenbrier's EBITDA was $129 million, representing 15% of revenue[5] - Operating cash flow was nearly $140 million[5] Orders and Backlog - New railcar orders totaled 3,900 units, valued at over $500 million[5] - Railcar deliveries amounted to 5,600 units[5] - The new railcar backlog stands at 18,900 units, with an estimated value of $2.5 billion[5] Capital Allocation and Liquidity - Greenbrier renewed and extended $850 million of bank facilities into 2030[5] - The company repurchased 507 thousand shares for nearly $22 million[5] - Available liquidity is approximately $770 million[6] Leasing and Fleet Management - Lease fleet utilization remained strong at 98%[5] - The company has a lease fleet of approximately 16,800 railcars[6, 11] - Recurring revenue grew by 45%[6] Operational Efficiency - Closure of one manufacturing facility in the European joint venture is expected to yield annual savings of at least $10 million[5]

Clinical Assets & Pipeline - Bosakitug (ATI-045) is a uniquely potent monoclonal antibody targeting TSLP, currently in a two-arm placebo-controlled Phase 2 trial initiated in Q2 2025 [6] - ATI-052, a bispecific antibody targeting both TSLP and IL-4R, has initiated a Phase 1a/1b SAD/MAD program in Q2 2025 [6] - ATI-2138, a potent and selective oral inhibitor of ITK/JAK3, expects top-line results from a Phase 2a OL trial in July 2025 [6] - The company is conducting discovery/preclinical evaluation for novel ITK inhibitors and BsAbs, with new INDs expected to start in 2026 [6] - Aclaris expects Phase 2a top-line results for ATI-2138 in Atopic Dermatitis in July 2025 [8, 11] Financial Position - Aclaris has a strong balance sheet and is expected to fund operations through the first half of 2028 [6] - The company anticipates opportunities for additional non-dilutive financing and development partners [6] - As of Q1 2025, Aclaris has $1905 million in cash, cash equivalents, and marketable securities [86] Bosakitug (ATI-045) Data - Bosakitug is reported to be >60x more potent than Tezepelumab in hPBMC CCL17 Inhibition [17] - Phase 2a trial data showed that 94% of patients achieved EASI 75 at Week 26 [37] - Phase 2a trial data showed that 65% of patients achieved EASI 90 at Week 26 [37] - Phase 2a trial data showed that 24% of patients achieved EASI 100 at Week 26 [37] - Phase 2a trial data showed that 88% of patients achieved IGA 0/1 at Week 26 [37] ATI-052 Data - ATI-052 is reported to be 3-5x more potent than the combination of Tezepelumab + Dupilumab on CCL17 release [54]

Financial Data and Key Metrics Changes - Net earnings for Q3 2025 were $60.1 million or $1.86 per share, showing an increase both sequentially and year-over-year [4] - Revenue reached $843 million, improving by 11% sequentially [21] - Aggregate gross margin remained robust at 18%, marking the seventh consecutive quarter at or above the mid-teens long-term target [4][22] - Return on invested capital (ROIC) was 12.9%, within the target range of 10% to 14% [23] Business Line Data and Key Metrics Changes - The manufacturing gross margin for Q3 was 13.6%, steady from Q2 [11] - Leasing and Fleet Management achieved nearly $165 million in recurring revenue over the last four quarters, representing nearly 50% growth from two years ago [12] - Fleet utilization remained high at 98%, with modest growth in the leased fleet [12] Market Data and Key Metrics Changes - Greenbrier secured orders for 3,900 new railcars worth over $500 million in the quarter, with a global new railcar backlog of nearly 19,000 units [15][16] - The average age of the North American railcar fleet exceeds 20 years, driving steady growth in the railcar maintenance market [17] - In Europe, railcar orders are driven by necessity, but overall activity is muted until economic conditions improve [18] Company Strategy and Development Direction - The company is focused on doubling recurring revenues by fiscal 2028 and has renewed two bank facilities totaling $850 million [7] - Greenbrier is investing in manufacturing and leasing, with expected investments of around $145 million in manufacturing and $270 million in leasing and fleet management [26] - The company is positioned to navigate various market conditions and capitalize on opportunities as they arise [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about a strong finish to the fiscal year and medium to long-term market conditions [10] - The Senate's passage of a budget bill is expected to energize markets for capital goods like railcars [9] - Management is confident in the ability to manage production rates in response to market demand and backlog visibility [38][40] Other Important Information - The company repurchased approximately $22 million in shares during the quarter, reflecting confidence in its long-term strategy [10][25] - Liquidity reached nearly $770 million, the highest level since 2023, consisting of almost $300 million in cash and over $470 million in available borrowing capacity [23][24] Q&A Session Summary Question: Clarification on interest and FX line items - Management expects interest expense to be in the 22% to 25% range for the quarter, with FX having a significant impact [31][32] Question: Production rates and order levels - Management has been adjusting production rates based on market demand and has a strong backlog of 19,000 cars, indicating optimism for future orders [38][40] Question: Confidence in backlog and order conversion - Management expressed confidence in the commercial team and anticipates that clarity around tariffs and trade policy will lead to increased orders [50][51] Question: Mix of deliveries and leased cars - Management noted that while leased fleet growth has been modest, they are becoming more active in the used car market to balance fleet growth [59]

Financial Data and Key Metrics Changes - Net earnings for Q3 2025 were $60.1 million or $1.86 per share, showing an increase both sequentially and year-over-year [5] - Revenue reached $843 million, improving by 11% sequentially [22] - Aggregate gross margin remained robust at 18%, marking the seventh consecutive quarter at or above the mid-teens long-term target [5][22] - Return on invested capital (ROIC) was 12.9%, within the target range of 10% to 14% [24] Business Line Data and Key Metrics Changes - The company delivered 5,600 new railcars in Q3, with a manufacturing gross margin of 13.6% remaining steady from Q2 [13] - Recurring revenue from leasing and fleet management reached nearly $165 million over the last four quarters, representing nearly 50% growth from two years ago [14] - Fleet utilization remained high at 98%, with modest growth in the leased fleet [14] Market Data and Key Metrics Changes - The global new railcar backlog stood at nearly 19,000 units, providing strong visibility in new railcar markets [18] - In Europe, railcar orders are driven by necessity, but activity is expected to be muted until economic conditions improve [19] - Demand in Brazil is modestly increasing as customers complete infrastructure investments [20] Company Strategy and Development Direction - The company is focused on doubling recurring revenues by fiscal 2028 and has renewed two bank facilities totaling $850 million [8] - Strategic initiatives include European footprint rationalization and North American insourcing projects, expected to yield annual savings of at least $10 million [6][7] - The company aims to maintain a disciplined approach to growing its lease fleet, ensuring predictable revenue and cash flow [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about market conditions in the medium to long term, anticipating a strong finish to the fiscal year [12] - The company is well-positioned to navigate various market conditions and capitalize on opportunities as liquidity is at its highest level since 2023 [9][11] - Management noted that the aging North American railcar fleet is a key driver for steady growth in the railcar maintenance market [18] Other Important Information - The company repurchased approximately $22 million of shares during the quarter, reflecting confidence in its long-term strategy [12] - The tax rate for the quarter was 23%, better than expected due to the strengthening Mexican peso [24] - The company updated its guidance, raising aggregate gross margin percent and operating margin percent for the remainder of fiscal 2025 [27] Q&A Session Summary Question: Guidance on interest and FX line items - Management expects interest expense to be in the 22% to 25% range for the quarter, with FX having a significant impact [31][32] Question: Production rates and order levels - Management has been adjusting production rates based on market demand and has a strong backlog of 19,000 cars, indicating future demand [38][40] Question: Confidence in order levels given low backlog - Management expressed confidence in converting demand into orders once trade policies stabilize, with several catalysts expected to drive demand [49][51] Question: Mix of deliveries and leased cars - The company is becoming more active in the used car market to balance its leasing business and is committed to growing the leasing fleet [58]

Energy Market Outlook - Global energy demand is projected to steadily grow, driven by developing economies like India (32% of incremental demand from 2017 to 2040), China (26%), and Africa (15%) [9, 12] - The U S is the largest oil and gas producer, with production up 23% and 29% respectively in 2017 compared to 2000 and 2010 [16, 17] - U S oil and natural gas production is expected to grow by approximately 33% from 2017 to 2025 [22] Kinder Morgan's Asset and Financial Highlights - Kinder Morgan transports approximately 40% of the natural gas consumed in the U S [26, 39] - The company's 2019 budgeted Segment EBDA is approximately $84 billion, with natural gas pipelines contributing 61%, products pipelines 15%, terminals 14%, CO2 oil production 6%, and CO2 S&T 4% [25] - Kinder Morgan anticipates $5 billion of distributable cash flow (DCF) in 2019, allocating approximately $2 billion for dividends and $3 billion to enhance shareholder value [30] - Approximately 96% of Kinder Morgan's 2019 budgeted segment cash flow is from take-or-pay and other fee-based contracts or hedged [33] Growth and Capital Allocation - Kinder Morgan has $61 billion of commercially secured capital projects underway, with $43 billion specifically for natural gas projects [44] - The company's capital allocation priorities include maintaining a strong balance sheet with a target Net Debt / Adjusted EBITDA of approximately 45x, dividend growth, and share repurchases [37, 38] - U S natural gas production is projected to grow by over 30 Bcfd, or approximately 37%, through 2030, driven by key basins [39] Financial Performance and Valuation - Kinder Morgan's 2019 budgeted Adjusted EBITDA is $78 billion, and distributable cash flow (DCF) is $50 billion [73] - The company's 2019 dividend is targeted at $100 per share, with a planned increase to $125 per share in 2020 [38] - Approximately 69% of Kinder Morgan's 2019 budgeted net revenue is generated by end-users [87]

Energy Market Overview - Global energy demand is expected to grow steadily, driven by population growth, urbanization, and economic development, with developing economies like India (32%), China (26%), Africa (15%), and Southeast Asia (15%) leading the increase from 2017 to 2040[9] - The U S is the largest oil and gas producer globally, with production expected to grow by approximately 33% by 2025, positioning it as a key trade partner[11, 15] - By 2025, the U S is projected to supply over 50% of the expected global supply increase and produce nearly 1 out of every 5 barrels of oil and 1 out of every 4 cubic meters of natural gas worldwide[15] Kinder Morgan's Business and Financial Highlights - Kinder Morgan is a leader in energy infrastructure, operating approximately 70,000 miles of natural gas pipelines and transporting about 40% of the natural gas consumed in the U S [20, 49] - The company anticipates approximately $5 billion in distributable cash flow (DCF) for 2019, allocating around $2 billion for dividends and $3 billion for enhancing shareholder value[21] - Kinder Morgan has a market capitalization exceeding $40 billion and boasts investment-grade rated debt, with recent upgrades to BBB / Baa2 by S&P and Moody's[24] - The company offers a current dividend yield of 5% based on a $20 share price, with a planned 25% dividend growth in both 2019 ($1 00/share) and 2020 ($1 25/share)[24, 30] - Kinder Morgan has repurchased approximately $525 million of its shares since December 2017 as part of a $2 billion share buyback program[24] Growth and Capital Projects - The company has $6 1 billion of commercially secured capital projects underway, primarily focused on natural gas opportunities[36] - U S natural gas production is projected to grow by over 30 Bcfd, nearly 40%, by 2030, with over 70% of the forecasted demand growth concentrated in Texas and Louisiana[33, 34] - Kinder Morgan is investing in Permian takeaway projects, including GCX and PHP, with a combined capacity of 4 1 Bcfd, and is in discussions for a potential third pipeline[40, 42] - The company's network is contracted for over 5 7 Bcfd of transport capacity to U S liquefaction facilities under 19-year average term contracts, with approximately $1 billion invested in transportation infrastructure to support LNG exports[49] Financial Performance and Stability - Approximately 90% of Kinder Morgan's earnings are underpinned by take-or-pay or fee-based contracts, ensuring stable cash flows[65] - The company projects approximately $8 billion in adjusted EBITDA for 2019[66] - Kinder Morgan has a long-term target net debt / adjusted EBITDA ratio of approximately 4 5x, which was reached as of March 31, 2019[30]

Financial Performance and Guidance - The company's 2021 budgeted Adjusted EBITDA is $6.8 billion, a decrease of approximately 2% compared to the 2020 forecast, reflecting headwinds from lower re-contracting rates and crude volumes[15] - 2021 Distributable Cash Flow (DCF) is budgeted at $4.4 billion, down approximately 3% from the 2020 forecast, also impacted by higher anticipated sustaining capex[15] - Net income for 2021 is projected to be greater than $2.1 billion, an increase primarily due to asset and goodwill impairments taken during 2020[15] - The company has a $2 billion share buyback program, with $575 million already purchased since December 2017[13] - The company maintains a current dividend yield of over 7%, with a Q3 2020 annualized dividend of $1.05 per share[14] Business Overview and Strategy - The company moves approximately 40% of U S natural gas consumption and exports[9] - Approximately 74% of the company's earnings are from take-or-pay or hedged contracts, providing stable cash flows[37, 48] - The company has commercially-secured capital projects underway totaling $2.6 billion as of September 30, 2020[23] - The company's business mix includes 62% natural gas, 15% products, 14% terminals, 6% CO2, and 3% oil & gas production[11] Market and Industry Trends - U S natural gas demand is expected to grow, with over 85% of the forecasted demand growth driven by Texas and Louisiana[18] - Global biofuels demand is expected to increase by approximately 146% from 2019 to 2040[46]

ARCT-810 Overview - Arcturus is a commercial mRNA medicines company with a pipeline of multiple therapeutic candidates in advanced clinical trial development[7] - ARCT-810 aims to restore OTC enzyme function, potentially preventing neurological damage and the need for liver transplantation in Ornithine Transcarbamylase (OTC) Deficiency patients[9] - ARCT-810 has received Orphan Drug Designation (FDA), Orphan Medicinal Product Designation (EMA), Fast Track Designation (FDA), and Rare Pediatric Disease Designation (FDA)[14, 15, 16, 17] Clinical Trial Results - European Phase 2 study (N = 8; 6 ARCT-810 / 2 placebo) is completed, and the U S Phase 2 study (N = 3 completed to date) is ongoing[20] - Combined analysis of both Phase 2 studies showed mean glutamine levels decreased significantly (N = 8, p-value = 0 0055)[25] - In the Phase 2 Open-label U S Study, mean glutamine levels decreased significantly (N = 3, p-value = 0 004), with all subjects achieving normal levels after three administrations[28] - Interim Phase 2 data from the U S Open Label Study (N = 3) showed a mean RUF (relative ureagenesis function) increase of +14 7% from baseline to 28 days post-fifth dose, from 29 0% (SD 9 1%) to 43 7% (SD 21 7%), which is statistically significant (p-value = 0 026)[31] Safety and Tolerability - ARCT-810 was generally safe and well-tolerated in Phase 2 studies at all tested dose levels, comprising 40 participants to date, including 20 OTC deficient participants[34, 35] KOL Insights - Glutamine rises earlier than ammonia in OTC deficiency and has lower variability, making it a reliable indicator of urea cycle stress[47] - 15N-Ureagenesis assay directly reflects cycle function, providing a clear readout of therapeutic efficacy[47]